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ABSTRACT
Purpose The goal of this study was to test the hypothesis that
by controlling intracellular uptake, organic cation transporter 1,
Oct1 is a key determinant of the disposition and toxicity of cis-
diammine(pyridine)chloroplatinum(II)(CDPCP) and oxaliplatin.
Methods Pharmacokinetics, tissue accumulation and toxicity
of CDPCP and oxaliplatin were compared between Oct1-/-
and wild-type mice.
Results After intravenous administration, hepatic and intestinal
accumulation of CDPCP was 2.7-fold and 3.9-fold greater in
Oct1 wild-type mice (p<0.001). Deletion of Oct1 resulted in
a significantly decreased clearance (0.444±0.0391 ml/min*kg
versus 0.649±0.0807 ml/min*kg in wild-type mice, p<0.05)
and volume distribution (1.90±0.161 L/kg versus 3.37±
0.196 L/kg in wild-type mice, p<0.001). Moreover, Oct1
deletion resulted in more severe off-target toxicities in CDPCP-
treated mice. Histologic examination of the liver and measure-
ments of liver function indicated that the level of hepatic toxicity
was mild and reversible, but was more apparent in the wild-
type mice. In contrast, the effect of Oct1 on the pharmaco-
kinetics and toxicity of oxaliplatin in the mice was minimal.
Conclusions Our study suggests that Oct1 plays an important
role in the pharmacokinetics, tissue distribution and toxicity of
CDPCP, but not oxaliplatin.
KEY WORDS OCT1 . pharmacokinetics . platinum agent .
toxicity . transporter
ABBREVIATIONS
ABC ATP Binding Cassette
CDPCP cis-Diammine(pyridine)chloroplatinum(II)
FBS fetal bovine serum
GAPDH glyceraldehydes-3-phosphate dehydrogenase
ICP-MS inductively coupled plasma mass spectrometry
ITS insulin-transferrin-selenium
Kim-1 kidney injury molecule-1
MPP+ N-methylquinine, and 1-methyl-4-phenylpyridinium
OCTs organic cation transporters
PK pharmacokinetics
qRT-PCR quantitative real-time polymerase chain reaction
SLC solute carrier
TEA tetraethylammonium
INTRODUCTION
Membrane transporters play important roles in drug
disposition and response (1–5). Recently, organic cation
transporter 1 (OCT1), encoded by SLC22A1, has been
shown to affect the pharmacokinetics and pharmacody-
namics of the anti-diabetic drug, metformin (6,7). In
humans, OCT1 is primarily expressed in the liver (8–10),
whereas in rodents, Oct1 is expressed in equal abundance
in the liver, kidney, and small intestine (11,12). In general,
the human OCT1 mediates intracellular uptake of a broad
range of structurally diverse monovalent organic cations
with molecular weights of less than 400 Daltons (13,14).
Substrates of OCT1 include endogenous compounds, such
as choline, creatinine, and monoamine neurotransmitters;
clinically used drugs, such as metformin, oxaliplatin and
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cimetidine; and a variety of xenobiotics, such as tetraethy-
lammonium (TEA, model cation), N-methylquinine, and 1-
methyl-4-phenylpyridinium (MPP+) (13,15,16). In vivo,
Oct1-/- mice display impaired liver uptake and intestinal
excretion of a subset of organic cations, such as TEA,
MPP+, and metformin (4,6,17), suggesting that the trans-
porter Oct1 is important for the uptake of certain xeno-
biotics and drugs into various tissues, including the liver in
the animal model.
Platinum-based chemotherapies have been widely used
to treat solid tumors since the 1970s (18). Although
cisplatin is effective against several solid tumors, its clinical
use is limited because of its toxic effects as well as the
intrinsic and acquired resistance of some tumors to this
drug (19). To overcome limitations related to toxicities and
resistance, other platinum agents have been developed (20).
Oxaliplatin, approved in 2002 for the treatment of
colorectal cancer in combination with 5-FU/leucovorin
(21), exhibits a different pattern of sensitivity to that of
cisplatin in the NCI60-cell human tumor panel, and in
combination with 5-FU/leucovorin produces response rates
twice that of 5-FU/leucovorin regimens alone in the
treatment of colorectal cancer, against which cisplatin is
inactive (20,22,23). Moreover, compared with cisplatin,
oxaliplatin shows a more favorable toxicity profile.
Cis-diammine(pyridine)chloroplatinum(II) (CDPCP),
belongs to a different series of platinum analogues from
cisplatin, carboplatin and oxaliplatin. In particular, it is a
cationic triamine complex that possesses desirable physical
properties, such as high stability and solubility in aqueous
media. Although CDPCP violates some of the classical
structure-activity relationship, its anti-cancer activity was
established in murine tumor models (24). However,
CDPCP has never been tested in humans, possibly
because this compound only forms monofunctional com-
plexes with DNA, and due to its polarity, the drug was not
expected to cross cell membrane readily (25). A recent
study, however, showed that CDPCP can largely escape
repair, yet inhibit transcription very effectively, and its
adducts should persist longer than those of cisplatin yet
produce a similar number of downstream consequences
that might raise the therapeutic potential of CDPCP
relative to cisplatin (25).
Recently, we showed that CDPCP is an excellent
substrate of OCT1 (25). When overexpressed in transfected
cells, OCT1 substantially increased the cellular uptake and
cytotoxicity of CDPCP, suggesting that OCT1 facilitates
intracellular accumulation of CDPCP, thereby sensitizing
the cells to CDPCP cytotoxicity. Our in vitro studies also
indicated that OCT1 facilitates the accumulation of
oxaliplatin, though the effect was much smaller in compar-
ison to CDPCP (15,25). Currently, there is an increased
interest in further developing CDPCP as an anti-cancer
drug regarding the high selectivity of CDPCP for cells
expressing hOCT1 and/or hOCT2, which are broadly
expressed in human liver, kidney and human colorectal
cancer (8–10,13,15).
In this study, we determined the pharmacokinetics and
toxic properties of CDPCP and oxaliplatin in mice and
tested the hypothesis that Oct1 plays a major role in the
pharmacokinetics and toxicities of these drugs using Oct1-/-
mice. Specifically, we examined the role of Oct1 in the
pharmacokinetics, tissue accumulation and toxicities of
CDPCP and oxaliplatin in Oct1-/- and wild-type mice.
Our results demonstrate that Oct1 plays an important role
not only in the pharmacokinetics of CDPCP, but also in its
toxicities. However, the role of Oct1 in the pharmacoki-
netics of oxaliplatin was proven to be minimal. Our study
sets the stage for further preclinical and clinical studies of
CDPCP.
MATERIALS AND METHODS
Drugs and Reagents
Oxaliplatin and disopyramide were purchased from Sigma
(St. Louis, MO). ITS (Insulin-Transferrin-Selenium) was
purchased from Invitrogen (Carlsbad, CA). CDPCP was
synthesized in our laboratory as described below. Solutions
of oxaliplatin (5 mM) and CDPCP (10 mM) were freshly
prepared in saline or PBS. The stock solutions were stored
frozen at −20°C and discarded after 1 month of prepara-
tion. The cell culture media DMEM H21 medium,
William’s E, heat-inactivated fetal bovine serum (FBS),
and L-glutamine were purchased from the Cell Culture
Facility of the University of California, San Francisco (San
Francisco, CA).
Synthesis of CDPCP
CDPCP was synthesized by a method adapted from Hollis
et al. (24). Briefly, to a solution of cisplatin (900 mg,
3 mmol) in 15 mL of anhydrous DMF, AgNO3 (485 mg,
2.85 mmol) was added at room temperature, and the
mixture was allowed to stir for 24 h. The resulting
precipitate of AgCl was removed by filtration before the
addition of pyridine (242 μL, 3 mmol) to the filtrate. After
the solution was stirred for an additional day, the DMF was
removed under vacuum, and the remaining oil was
triturated with CH2Cl2 (100 mL), followed by trituration
with diethyl ether (50 mL). The resulting solid was filtered
and then recrystallized from hot methanol to obtain
product cis-[Pt(NH3)2(Pyr)Cl](NO3) as a light yellow solid
(yield 720 mg, 1.77 mmol, 59%). 1H NMR (400 MHz,
D2O) δ8.90 (m, 1H, Ar), 8.45 (m, 2H, Ar), 7.31 (m, 2H,
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Ar), 4.72, 4.26 (bs, 3H, NH3); ESI-MS 343.1 [M]
+;
Elemental Analysis: Found (%) C, 15.12; H, 2.50; N,
13.62. Calculate for C5H11ClN4O3Pt (%): C, 14.80; H,
2.73; N, 13.81.
Cell Lines and Transfection
Human embryonic kidney (HEK) 293 cells stably trans-
fected with the full-length reference human OCT1 cDNA
(HEK-hOCT1) and with the empty vector (HEK-MOCK)
were established previously in our laboratory (6,15).
HEK293 cells stably transfected with pcDNA5/FRT vector
(Invitrogen) containing the full-length reference mouse
Oct1 cDNA (HEK-mOct1) were established using Lipofect-
amine 2000 (Invitrogen) per manufacturer’s instructions. The
stable clones were selected with 75 μg/ml hygromycin B.
Primary Mouse Hepatocytes
Primary hepatocytes were isolated from Oct1+/+ and
Oct1-/- mice by the UCSF Liver Center using the standard
collagenase method (26). For the CDPCP uptake assay, the
isolated primary hepatocytes were seeded onto collagen-
coated 6-well plates (Becton Dickenson, Bedford, MA) at a
density of 0.8×106 cells/well in culture medium. After
attachment (2–3 h), the cells were maintained in fresh
medium for another 16–24 h followed by drug treatment as
described below. For the uptake of oxaliplatin, the freshly
isolated hepatocytes in suspension (1.5×105 cells/tube)
instead of attached cells were used. During the incubation,
the suspended cells were mixed several times by gentle
vortex.
Cell Culture
The culture medium for stably transfected cells was DMEM
H21 medium supplemented with 10% FBS, 100 units/ml
penicillin and 100 μg/ml streptomycin and 60 μg/ml
hygromycin B. The culture medium for primary hepato-
cytes was William’s E medium supplemented with 100
units/ml penicillin, 100 μg/ml streptomycin, 10% fetal
bovine serum (FBS), 0.1 μM dexamethasone, 2 mML-
glutamine, 1X ITS (100X ITS from Invitrogen). All cell
lines were grown at 37°C in a humidified atmosphere with
5% CO2.
Cellular Accumulation of Platinum
The cellular accumulation of platinum was determined as
described previously (15) with some modifications. Briefly,
the cells were incubated in serum-free culture medium
containing the indicated platinum compounds with or
without a specific inhibitor at 37°C in 5% CO2 for 1 h
unless specified. After incubation, cells were washed with
ice-cold PBS three times. Then the cells were dissolved in
100 μl of 70% nitric acid at 65°C for at least 2.5 h. Distilled
water containing 10 ppb of iridium (Sigma) and 0.1%
Triton X-100 was added to the samples to dilute nitric acid
to 7%. The platinum content was measured by inductively
coupled plasma mass spectrometry (ICP-MS) in the
Analytical Facility at the University of California at Santa
Cruz (Santa Cruz, CA). Cell lysates from a set of identical
cultures were used for BCA protein assay. Cellular
platinum accumulation was normalized to the protein
content.
Platinum-DNA Adduct Formation
The platinum content associated with genomic DNA was
determined as described previously (15) with some mod-
ifications. Briefly, the cells were incubated in the serum-free
culture medium containing platinum drugs with or without
an OCT1 inhibitor at 37°C in 5% CO2 for 1 h unless
specified. After incubation, cells were washed three times
with ice-cold PBS. Genomic DNA was isolated from the
cells using Wizard Genomic DNA Purification kit (Prom-
ega, Madison, WI) according to the manufacturer’s
protocol. The DNA-bound platinum was determined by
ICP-MS. The DNA content from the same DNA prepara-
tion was measured by absorption spectroscopy at 260 nm.
Platinum-DNA adduct level was normalized to total DNA
content.
RNA Isolation
Total RNA from primary hepatocytes was isolated using an
RNeasy Mini kit (Qiagen, Valencia, CA) according to the
manufacturer’s protocols. Total RNA from tissues was
extracted using Trizol (Invitrogen). During the RNA
purification procedure, DNase I was treated to digest
residual genomic DNA. RNA was quantified spectropho-
tometrically at 260 nm. Extracted RNA was stored at
−80°C until use.
Quantitative Real-Time PCR
Five μg of total RNA from each sample was reverse
transcribed into cDNA using a superscript first-strand
cDNA synthesis kit (Invitrogen, Carlsbad, CA) according
to the manufacturer’s protocol. Quantitative real-time PCR
(qRT-PCR) was carried out in a 96-well plate in a total
volume of 10 μl reaction solution which includes a cDNA
equivalent of 2 μg total RNA, specific probe and Taqman
Universal Master Mix (Applied Biosystems, Foster City,
CA). The thermal cycling conditions (ABI Prism 7700) were
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95°C for 20 s followed by 40 cycles of 95°C for 3 s and
60°C for 30 s. The amplification of glyceraldehydes-3-
phosphate dehydrogenase (GAPDH) mRNA was used as an
internal control.
Animals
Oct1-/- mice were generated as described elsewhere (6).
The animals used in all experiments were in FVB
background and were age-matched Oct1-/- and Oct1+/+
(wild-type) mice between 8 and 10 weeks of age. All
animals were housed in a virus-free, temperature-
controlled facility on a 12-h light-dark cycle. Mice were
allowed standard mouse food and water ad libitum. All
experiments on mice were approved by the Institutional
Animal Care and Use Committee of University of
California at San Francisco and carried out according to
the “Principles of Laboratory Animal Care” (NIH
publication #85-23, revised in 1985).
Tissue Accumulation Studies in Mice
Eight-week-old male Oct1+/+ and Oct1-/- mice were given
platinum drugs in saline via tail vein injection. The animals
were sacrificed at different time points after treatment.
Blood samples were collected by heart puncture and
transferred into heparinized BD vacutainer blood collection
tubes. Blood was centrifuged for 30 min at 1000 x g, and
the plasma was decanted and frozen at −80°C until
analysis. Tissues (liver, kidney, heart, lung, brain, intestine,
spleen and muscle) were collected as quickly as possible and
snap frozen in liquid nitrogen. Five μl of plasma and about
10–30 mg of tissues were used for total platinum measure-
ment by ICP-MS.
Pharmacokinetics Study in Mice
Eight-week-old male Oct1+/+ and Oct1-/- mice were given
platinum drugs in saline via tail vein injection and placed in
metabolic cages for 24 h. Blood samples (20 μl) were
collected at different time points by tail vein bleeding
into heparinized micro-hematocrit capillary tubes (Fisher,
Pittsburg, PA). Blood was centrifuged for 5 min using
Microhematocrit Centrifuge (Thermo Fisher Scientific Inc.
Waltham, MA), and the plasma was decanted and frozen at
−80°C until analysis. Urine was collected from tubes
attached to the cages. Tissues (liver, kidney, intestine,
muscle) were collected as quickly as possible upon the last
time point and snap frozen in liquid nitrogen. Five μl of
plasma, urine and about 10–30 mg of tissues were used for
total platinum measurement by ICP-MS. The pharmaco-
kinetics parameters were obtained by two-compartmental
analysis using WinNonlin 4.0 (Pharsight Corporation,
Mountain view, CA).
Toxicity Study in Mice
Eight-week-old male Oct1-/- and Oct1+/+ mice were
randomized and treated with saline or platinum drugs via
tail vein injection (CDPCP) or i.p. injection (oxaliplatin)
once weekly for a total of 3 weeks (CDPCP) or once daily
for a total of 5 days (oxaliplatin). The animals were closely
monitored and sacrificed when they became moribund.
Body weight was monitored and recorded. All surviving
animals were sacrificed 24 h after the last treatment. On the
day of the terminal sacrifice, the animals were anesthetized
with isoflurane, and blood (500–1000 μl) was collected by
heart puncture and centrifuged for 30 min at 1000 X g at
4°C. The serum was frozen at −80°C until analysis. Tissues
(liver, kidney, intestine, and muscle) were collected and
divided into two halves: one half of the tissues were fixed in
4% paraformaldehyde for histopathology examination, and
the other half of the tissues were snap frozen in liquid nitrogen.
Hematological Evaluation
The whole blood (50–100 μl) was placed in K2EDTA
coated tubes, and complete blood count (CBC) tests were
conducted within 6 h by Mouse Pathology Core of UCSF
Helen Diller Family Comprehensive Cancer Center.
Clinical Chemistry Evaluation
Alaninetransaminase (ALT), aspartatetransaminase (AST),
alkaline phosphatase (ALKP), total protein, albumin,
glucose, blood urea nitrogen (BUN), creatinine and electro-
lytes in serum were measured by the Clinical Laboratory of
the San Francisco General Hospital.
Histopathological Examination
The tissues (liver, intestine and kidney) fixed in 4%
paraformaldehyde were embedded in paraffin, cut into
thin sections and mounted on glass slides. The tissue
sections were stained with hematoxylin and eosin for
microscopic examination.
Statistical Analysis
Unless specified, data are expressed as mean ± standard
deviation (SD). Data were analyzed statistically using the
unpaired Student’s t-test and Fisher exact test according to
the sample size. Multiple comparisons were performed with
Dunnett’s two-tailed test after one-way ANOVA. A p value
of less than 0.05 was considered statistically significant.
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RESULTS
Platinum Uptake in Cells Over-Expressing hOCT1
and mOct1 After Exposure to CDPCP and Oxaliplatin
As shown in Fig. 1a, we observed that the uptake of
platinum in HEK-mOct1 transfected cells exposed to
CDPCP (10 μM) (1470±66.6 pmol/mg protein/hr) was
53-fold greater than that in HEK-MOCK cells (27.4±7.43
pmol/mg protein/hr) (p<0.001). This effect was slightly
greater than the effect of hOCT1 on platinum uptake
after exposure to CDPCP (10 μM) (852±135 pmol/mg
protein/hr). The effect of hOCT1 and mOct1 on the
cellular uptake of oxaliplatin was much smaller than on
CDPCP uptake, and, again, mOct1, in comparison to
hOCT1, promoted a greater uptake of platinum in cells
exposed to oxaliplatin (p<0.001; Fig. 1b).
Intracellular Platinum Uptake and DNA Adduct
Formation of Platinum Drugs in Primary Mouse
Hepatocytes
To examine the role of Oct1 in the disposition of CDPCP in
the liver, we compared the intracellular uptake and DNA
adduct formation of CDPCP in hepatocytes derived fromOct1
wild-type mice with that in hepatocytes derived from Oct1-/-
mice. The studies showed that the hepatocellular uptake of
CDPCP (10 μM) after 1 hr exposure in hepatocytes from
Oct1 wild-type mice (251±94.6 pmol/mg protein/hr) was
2.9-fold of that in hepatocytes from Oct1 -/- mice (87.8±7.61
pmol/mg protein/hr) (p<0.01; Fig. 2a). Co-incubation of
CDPCP with disopyramide (150 μM), an Oct1 inhibitor,
resulted in a 4.5-fold decrease in the platinum uptake in
hepatocytes from Oct1 wild-type mice (control versus disopyr-
amide-treated, 251±94.6 pmol/mg protein/hr versus 55.9±
1.41 pmol/mg protein/hr) (p<0.01) with no effect in
hepatocytes from Oct1-/- mice (control versus disopyramide-
treated, 87.8±7.61 pmol/mg protein/hr versus 95.8±17.6
pmol/mg protein/hr) (p>0.05; Fig. 2a). The platinum-DNA
adduct level after 1 h exposure to CDPCP in hepatocytes
from Oct1 wild-type mice (0.0857±0.0232 pmol/μg DNA)
was 2.4-fold greater than that in hepatocytes from Oct1-/-
mice (0.0351±0.00344 pmol/μg DNA) (p<0.01; Fig. 2b).
Co-incubation of CDPCP with disopyramide (150 μM)
significantly decreased (3.7-fold; p<0.01) platinum-DNA
adduct formation in hepatocytes from Oct1 wild-type mice
(control versus disopyramide treated, 0.0857±0.0232 pmol/μg
DNA versus 0.0233±0.00847 pmol/μg DNA) (p<0.01) with
no effect in hepatocytes from Oct1-/- mice (control versus
disopyramide-treated, 0.0351±0.00344 pmol/μg DNA
versus 0.0338±0.00798 pmol/μg DNA) (p>0.05; Fig. 2b).
Collectively, data shown in Fig. 2a and b suggest that Oct1
mediates the uptake and binding to DNA of CDPCP in
mouse hepatocytes.
For oxaliplatin, the intracellular uptake rate of platinum
increased proportionally with increasing concentrations of
oxaliplatin in hepatocytes isolated from both Oct1+/+ and
Oct1-/- mice (Fig. 2c and d). In all hepatocytes isolated
from Oct1+/+ and Oct1-/- mice, the intracellular uptake
rate of oxaliplatin was similar between 30 min exposure
and 120 min exposure. Compared to hepatocytes isolated
from Oct1-/-mice, hepatocytes isolated from Oct1+/+ mice
had significantly higher platinum uptake rate after incuba-
tion with 1 μM and 5 μM of oxaliplatin for 30 min and
120 min. The hepatocellular uptake rate of oxaliplatin after
30 min exposure in hepatocytes from Oct1 wild-type mice
(1 μM versus 5 μM, 1.54±0.300 pmol/mg protein/hr versus
5.55±0.384 pmol/mg protein/hr) was 1.8-fold and 1.4-fold
of that in hepatocytes from Oct1 -/- mice (1 μM versus
5 μM, 0.855±0.184 pmol/mg protein/hr versus 3.97±
0.500 pmol/mg protein/hr), respectively (p<0.05; Fig. 2c).
Similar results were obtained after 120 min of exposure
(Fig. 2d). These data indicate that Oct1 is likely to play a
role in facilitating the transport of oxaliplatin across
Fig. 1 Intracellular uptake of platinum after 1-h exposure to platinum drugs in cells over-expressing hOCT1 and mOct1. The cellular uptake of platinum
in hOCT1-transfected (striped bar), mOct1-transfected (solid bar) cells and in the corresponding MOCK (white bar) cells after incubation with CDPCP (A)
and oxaliplatin (B) were determined as described in Materials and Methods. Briefly, the cells were incubated in serum-free culture medium containing
CDPCP (10 μM) or oxaliplatin (10 μM) at 37°C and 5% CO2 for 1 h. Total platinum concentration inside the cells was determined using ICP-MS.
Total platinum concentration was normalized to protein content. Data are presented as the mean ± SD (n=6). a: significantly greater than in MOCK cells
(P<0.001); b: significantly greater than in hOCT1-transfected cells (P<0.001).
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hepatocytes. However, the effect of Oct1 on oxaliplatin
uptake is less than its effect on CDPCP uptake.
Tissue Accumulation of Platinum
After Treatment with Platinum Drugs in Oct1
Wild-Type and Oct1-/- Mice
To extend the in vitro cellular studies, we examined the role of
Oct1 in the accumulation of platinum drugs in various
tissues after dosing to Oct1 wild-type and Oct1-/- mice
(Fig. 3). The tissue accumulation study of CDPCP (8 mg/kg)
showed that total levels of platinum in the plasma 1 h after
CDPCP treatment were significantly higher (1.3-fold) in
Oct1-/- mice than in Oct1 wild-type mice (Fig. 3a, p<0.001).
Comparing the absolute platinum level in various tissues
(Table 1 and Fig. 3a), we observed that the platinum
accumulation levels in liver and intestine were significantly
higher in Oct1 wild-type mice than in Oct1-/- mice (p<0.01).
However, the platinum accumulation levels in kidney, heart
and skeletal muscle in Oct1 wild-type mice were significantly
lower than in Oct1-/- mice (p<0.05). When the absolute
platinum level in the various tissues was normalized to the
corresponding plasma concentration (Table 1 and Fig. 3b),
we observed that platinum levels in the muscle and kidney
were no longer significantly different between Oct1 wild-type
and Oct1-/- mice (p>0.05), while the normalization to
plasma concentration had no effect on the platinum
accumulation level in the heart (p<0.01). The normalized
platinum accumulation was 2.7-fold greater in the liver of
Oct1 wild-type compared to the knockout mouse and 3.9-fold
greater in the intestine of Oct1 wild-type compared to
knockout mice. The highest platinum accumulation levels
were found in liver and intestine in both Oct1 wild-type and
Oct1-/- mice (Table 1). Taken together, this study suggests
that the expression of Oct1 in liver and intestine contributes
to the enhanced accumulation of CDPCP in these organs.
The effect of OCT1 on the tissue distribution of
oxaliplatin was first examined 6 h after intravenous dosing
of oxaliplatin (8 mg/kg). The absolute platinum levels and
the platinum levels normalized to plasma platinum concen-
trations in various tissues including liver, kidney, intestine,
spleen, bone marrow and muscle showed no significant
difference between Oct1+/+ and Oct1-/- mice (p>0.05).
The effect of Oct1 on the tissue distribution of oxaliplatin
was reexamined after a shorter treatment duration. After
1 h treatment with oxaliplatin (8 mg/kg), the plasma
concentration of oxaliplatin in Oct1+/+ was slightly but
significantly lower than that in Oct1-/- mice (Oct1+/+ versus
Oct1-/-, 5.96±0.54 μM versus 6.69±0.62 μM; p<0.05;
Fig. 3c). Comparing the oxaliplatin accumulation in various
tissues, we observed that the absolute oxaliplatin levels in
intestine, kidney and heart in Oct1-/- mice were signifi-
cantly higher than in Oct1+/+ mice (Fig. 3c; p<0.05).
However, after normalization with corresponding plasma
Fig. 2 Effect of Oct1 on the
intracellular uptake of platinum in
primary mouse hepatocytes after
exposure to CDPCP and oxali-
platin. Intracellular platinum uptake
(A) and platinum-DNA adduct
formation (B) after 1 h exposure
to 10 μM CDPCP in the absence
(white bars) or presence (black
bars) of an Oct1 inhibitor, diso-
pyramide (150 μM) and intracel-
lular platinum uptake after 30 min
(C) and 120 min (D) exposure to
1 μM and 5 μM of oxaliplatin in
hepatocytes from Oct1 wild-type
(white bars) and Oct1-/- mice
(black bars) were determined as
described in Materials and Meth-
ods. Total platinum concentration
inside the cells and DNA-bound
platinum was determined using
ICP-MS. Total platinum concen-
tration was normalized to protein
content, and DNA-bound plati-
num was normalized to DNA
content. Data are presented as
the mean ± SD (n=3) and
from a representative experiment.
* P<0.05, ** P<0.005.
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concentrations, the differences in renal, cardiac, and
intestinal accumulation between Oct1+/+ and Oct1-/- mice
were not observed (Fig. 3d).
Platinum accumulation in various tissues was also
measured at the end of pharmacokinetics studies, i.e. 48 h
after dosing. The effects of Oct1 on the tissue accumulation
of platinum drugs were similar to the data obtained at
1 h for both CDPCP and oxaliplatin, i.e. Oct1 enhanced
the hepatic and intestinal accumulation of CDPCP, and
exerted insignificant effect on the oxaliplatin accumulation.
Pharmacokinetics of Platinum Drugs in Oct1
Wild-Type and Oct1-/- Mice
The time-course of platinum in plasma following a single
i.v. dose of CDPCP (8 mg/kg) to Oct1 wild-type and Oct1-/-
mice is shown in Fig. 3e. Similar to the pharmacokinetics of
AMD473 (picoplatin), a third-generation platinum agent,
which is currently in Phase-III clinical trials for treatment of
non-small-cell lung cancer (NSCLC) (27,28), the concen-
tration versus time course of total platinum followed a two-
Fig. 3 Effects of Oct1 on tissue accumulation of platinum drugs and plasma concentrations after intravenous dosing of CDPCP and oxaliplatin in mice.
Absolute platinum accumulation levels (A, C), normalized platinum accumulation levels (B, D) in various tissues were measured 1 h post dosing of 8 mg/
kg of CDPCP (A, B) and oxaliplatin (C, D), respectively in Oct1wild-type and Oct1-/- mice. Plasma concentrations of CDPCP (E), oxaliplatin (F) in
Oct1wild-type and Oct1-/- mice were measured at 15, 30 min, 1, 2, 3, 4, 8, 10, 24, 48 hr after i.v. dosing of CDPCP (8 mg/kg) and oxaliplatin (8 mg/kg).
The platinum levels in plasma and various organs were determined using ICP-MS. The unit for tissue accumulation of platinum is nmol/gram tissue, the
unit for plasma is μM (A, C). Data are presented as the mean ± SD * P<0.05; ** P<0.001.
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compartment model in both Oct1 wild-type and Oct1-/-
mice. The mean plasma concentrations of CDPCP in
Oct1-/- mice were significantly higher than that in Oct1
wild-type mice at all time pointes (Fig. 3e). The mean
pharmacokinetics parameters are shown in Table 2. Com-
paring the pharmacokinetics parameters of CDPCP in Oct1
wild-type mice with Oct1-/- mice, we observed that the
plasma platinum exposure over 48 hrs (AUC0-48) in Oct1-/-
mice was 1.69-fold of that in Oct1 wild-type mice
(p<0.01), and the volume of distribution of CDPCP in
Oct1 wild-type mice was 1.77-fold of that in Oct1-/- mice
(p<0.01). Moreover, a significantly greater total clearance
was observed in Oct1 wild-type mice in comparison to
Oct1-/- mice (p<0.05), although renal clearance showed no
difference between Oct1+/+ mice and Oct1-/- mice. The
renal clearance contributed to about 50% of the total
clearance of platinum from plasma in both Oct1+/+ and
Oct1-/- mice.
Consistent with the pharmacokinetics of CDPCP and
the previous report of oxaliplatin pharmacokinetics in rats
(29), the concentration versus time course of total platinum
following i.v. administration of oxaliplatin (8 mg/kg)
exhibited a biexponential decline in both Oct1 wild-type
and Oct1-/- mice (Fig. 3f). The pharmacokinetics parame-
ters were not significantly different between Oct1+/+ and
Oct1-/- mice, as shown in Table 3. The clearance and
volume of distribution of oxaliplatin in both Oct1+/+ and
Oct1-/- mice were similar to that reported in BD2F1 mice
(30).
Toxicity Study of CDPCP in Oct1 Wild-Type
and Oct1-/- Mice
Based on the results of the dose-range finding toxicity study
that CDPCP at 90 mg/kg and above resulted in significant
changes in body weight, liver-to-body-weight ratio, liver
function and hematology, we selected doses between
90 mg/kg and 120 mg/kg for use in evaluating the role
of Oct1 in CDPCP toxicity. The role of Oct1 in toxicity of
CDPCP was determined by comparing the toxicity profile
of CDPCP between Oct1+/+ and Oct1-/- mice. The dose
of CDPCP started with 120 mg/kg, which later was
reduced to 90 mg/kg due to death or moribundity observed
in Oct1-/- mice at 120 mg/kg.
CDPCP Resulted in Much Greater Body Weight Loss
in Oct1-/- Mice
Compared with saline control group, CDPCP treatment
caused body weight loss in both Oct1+/+ and Oct1-/- mice
(Fig. 4a). However, the body weight loss was much greater
in Oct1-/- mice than in Oct1+/+ mice. The greater
decrease in body weight in Oct1-/- mice treated withT
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CDPCP was consistent with the higher plasma platinum
concentration in these mice (p<0.005; Fig. 6a).
Hepatic Toxicity of CDPCP was Enhanced in Oct1+/+
Mice
The liver-to-body-weight ratio was significantly increased
compared to saline control in both Oct1+/+ and Oct1-/- mice
(Fig. 4b). However, the liver-to-body-weight ratio change in
Oct1+/+ mice, which was 28.8% increase in CDPCP-treated
mice compared with saline-treated mice, was more striking
than that in Oct1-/- mice, which was 14.7% increase in
CDPCP-treated mice compared with saline-treated mice. To
exclude the confounding effect of less body weight decrease
in Oct1+/+mice on the liver-to-body-weight ratio, the actual
liver weights between Oct1+/+ and Oct1-/- mice treated with
CDPCP and saline were also compared. Our data showed
that the actual liver weight was increased by CDPCP
treatment in Oct1+/+ mice but not in Oct1-/- mice (CDPCP
versus saline: 1.23 g versus 0.973 g in Oct1+/+ mice,
p<0.00001; 1.02 g versus 1.00 g in Oct1-/- mice, p>0.05),
indicating that CDPCP indeed resulted in hepatomegaly in
Oct1+/+ mice. Moreover, CDPCP resulted in significant
decrease in total serum protein levels and significant increase
in glucose levels in Oct1+/+ mice, but not in Oct1-/- mice
(Fig. 4c, d). However, the activities of ALT, AST and
ALKP were not affected by CDPCP in either Oct1+/+ or
Oct1-/- mice (Fig. 4e).
Histopathological examination of liver from Oct1-/- mice
treated with either saline or CDPCP showed no clear signs
Table 2 Plasma Platinum Pharmacokinetic Parameters Following a Single IV Administration of CDPCP (8 mg/kg) in Oct1+/+ and Oct1-/-mice
(3 Per Group)
Oct1+/+ Oct1-/- Oct1-/-/Oct1+/+ P value
Mean ± SD Mean ± SD
AUC0-48 (μM*hr) 257±7.10 434±29.4 1.69 0.009
AUCinf (μM*hr) 604±70.9 878±74.4 1.45 0.009
CL (ml/min*kg) 0.649±0.0807 0.444±0.0391 0.68 0.017
CLR(ml/min*kg) 0.320±0.246 0.221±0.177 0.69 0.603
VSS (L/kg) 3.37±0.196 1.90±0.161 0.56 0.0006
Cmax (μM) 17.9±2.21 43.1±7.68 2.41 0.005
T1=2;aðhrÞ 0.639±0.0324 0.494±0.137 0.77 0.37
T1=2;bðhrÞ 66.6±9.75 48.3±6.84 0.73 0.20
Blood samples for pharmacokinetic analysis were drawn up to 48 h. The pharmacokinetic parameters were obtained by two compartmental analysis using
WinNonlin 4.0.
T1=2;a, distribution half life; T1=2;b , terminal half life; Cmax, maximal plasma concentration; AUCinf, area under the curve of plasma concentration from time
0 to infinity; VSS, volume of distribution at steady state; CL, clearance; CLR, renal clearance.
Table 3 Plasma Platinum Pharmacokinetic Parameters Following a Single iv Administration of Oxaliplatin (8 mg/kg) in Oct1+/+ and Oct1-/-Mice (3 Per
Group)
Oct1+/+ Oct1-/- Oct1-/-/Oct1+/+ P value
Mean ± SD Mean ± SD
AUC0-48 (μM*hr) 118.7±4.37 118.5±7.74 1.00 > 0.05
AUC (μM*hr) 147±5.86 144±16.0 0.98 > 0.05
CL (ml/min*kg) 2.29±0.0916 2.35±0.270 1.03 > 0.05
CLR(ml/min*kg) 0.789±0.267 1.09±0.581 1.43 > 0.05
VSS (L/kg) 3.80±0.0950 3.56±0.168 0.94 > 0.05
Cmax (μM) 23.9±3.39 30.4±4.35 1.28 > 0.05
T1=2;aðhrÞ 0.374±0.0372 0.332±0.0772 0.89 > 0.05
T1=2;bðhrÞ 20.6±0.818 19.2±2.42 0.93 > 0.05
Blood samples for pharmacokinetic analysis were drawn up to 48 h. The pharmacokinetic parameters were obtained by two compartmental analysis using
WinNonlin 4.0.
T1=2;a, distribution half life; T1=2;b , terminal half life; Cmax, maximal plasma concentration; AUCinf, area under the curve of plasma concentration from time
0 to infinity; VSS, volume of distribution at steady state; CL, clearance; CLR, renal clearance.
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of toxicity, while the liver from Oct1+/+ mice treated with
CDPCP appeared to have enlarged and rounded hepato-
cytes, which are normally hexagonal (Fig. 4f). The irregular
white spots, which were considered to be aqueous materials
inside the hepatocytes pushed the nucleus aside, indicating
CDPCP resulted in liver edema in Oct1+/+ mice. The
hepatic lesion was more striking in the portal vein area than
in other regions of the liver. Comparing the frequency and
the severity of hepatic lesions, we observed that CDPCP
caused more severe and frequent liver damage in Oct1+/+
mice in comparison to Oct1-/- mice, as indicated by mild to
moderate swollen hepatocytes (Table 4). The differences
did not reach statistical significance using Fisher exact test
(p=0.07), though trends were apparent. The greater
hepatic toxicity in Oct1+/+ mice was consistent with the
higher absolute hepatic platinum accumulation in these
mice (Fig. 6b; p<0.005). Further, at higher doses of
CDPCP (120 mg/kg) used in our dose-finding studies, we
observed significant increases in ALT in the wild-type, but
not in the knockout, mice (data not shown). These data
strongly suggest that Oct1 deletion protects animals from
developing liver toxicity and that Oct1 plays a role not only
in CDPCP disposition but also in CDPCP-associated organ
toxicity.
Fig. 4 Effects of Oct1 on body weight loss and liver toxicities of CDPCP in mice. Oct1-/- andOct1+/+ mice were treated with saline or CDPCP via tail
vein injection once weekly for a total 3 weeks (at least 9 animals per group). The mice were fasted for at least 16 h before sacrifice. Body weight (A) was
monitored three times per week. Blood and various tissues were collected 24 hrs after the last dose; liver weight was measured. Liver to body weight
ratios (B), total protein levels in serum (C), glucose levels in serum (D) and activities of liver enzymes (E), were compared among groups. Liver
histopathology (F) was examined; the magnification is 40X. Data are presented as the mean ± SD (n≥9). * P<0.05; ** P<0.001.
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Renal Toxicity of CDPCP was More Pronounced
in Oct1-/- Mice
In both Oct1+/+ and Oct1-/- mice administered CDPCP,
serum creatinine levels were not significantly different from
mice administered saline (p>0.05; Fig. 5a). Serum BUN
levels were significantly reduced in CDPCP-treated
Oct1+/+ mice compared with saline-treated Oct1+/+ mice
(p<0.05), while serum BUN was not affected by CDPCP in
Oct1-/- mice (p>0.05; Fig. 5a). CDPCP treatment in-
creased renal mRNA levels of Kim-1, a more sensitive and
quantitative renal biomarker of early tubular damage, by
19.3-fold over control value in Oct1+/+ mice. However,
the elevation of renal Kim-1 expression in Oct1-/- mice
following CDPCP treatment was much more striking than
in Oct1+/+ mice; the fold difference over saline control was
117 (Fig. 5b).
Histologic evaluation of kidneys from CDPCP-treated
mice demonstrated tubular cast formation, which was
revealed by eosinophilic amorphous material and pyknotic
and karyorhectic debris (Fig. 5c.II) and degeneration of
tubular cells, including tubular dilatation, tubular cell
vacuolation, tubular cell detachment (Fig. 5c.III). The renal
morphology change seemed to localize to the outer medulla
Table 4 Histopathological Examination of Liver and Kidney in Oct1+/+ and Oct1-/-Mice Following Repeated i.v. Doses of CDPCP
Genotype Treatment Liver Kidney
OCT1+/+ CDPCP Severe swollen hepatocytes (3/4); Mild swollen
hepatocytes(1/4)
Normal (4/4)
Saline Mild swollen hepatocytes(1/5) Inflammation foci (1/5) Normal (5/5)
OCT1-/- CDPCP Mild swollen hepatocytes(1/4) Kidney tube protein contents (3/4); kidney hyaline necrosis (1/4)
Saline Multiple necrosis + inflammation foci (1/4) Normal (4/4)
Livers and kidneys were harvested 24 hr following the third dose of CDPCP and fixed in 4% paraformaldehyde for histopathology examination. The
denominator in the parenthesis represents the total number of animals that were examined. The numerator represents the number of animals that were
affected.
Fig. 5 Effect of Oct1 on renal toxicity of CDPCP in mice. Oct1-/- and Oct1+/+ mice were treated with saline or CDPCP via tail vein injection once
weekly for a total 3 weeks (at least 9 animals per group). The mice were fasted for at least 16 h before sacrifice. Blood and various tissues were collected
24 hrs after the last dose. Creatinine and BUN in serum (A) were measured. Total RNA from kidney was reverse-transcribed and the synthesized cDNA
was subject to qRT-PCR using Kim-1 (B) probe. The amplification of glyceraldehydes-3-phosphate dehydrogenase (GAPDH) mRNA was used as an
internal control. Kidney histopathology (C) was examined; the magnification is 20X; arrows indicate kidney lesions. Data are presented as the mean ± SD.
* P<0.05; a: significantly greater than corresponding saline control groups (P<0.01); b: significantly greater than Oct1+/+ mice (P<0.05).
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(Fig. 5c.II and c.III). Consistent with the Kim-1 expression
study, the kidney tubular lesions were most prominent in
Oct1-/- mice treated with CDPCP compared with Oct1+/+
mice treated with CDPCP (Fig. 5c.I) and saline-treated
control animals. The incidence and type of kidney lesion are
listed in Table 4. We observed that CDPCP treatment
resulted in a lower rate of kidney damage in Oct1+/+ mice
than in Oct1-/- mice, and the rate difference was marginally
significant (p=0.07). The absolute renal platinum accumula-
tion in Oct1-/- mice was remarkably greater than that in
Oct1+/+ mice (Fig. 6c; p<0.05). These data indicate that
CDPCP is more toxic to the kidney in Oct1-/- mice.
Toxicities of CDPCP in Other Sites
The hematological toxicity of CDPCP was more pro-
nounced in Oct1-/- mice, which was reflected by significant
changes in white blood cell parameters, including neutro-
phil (%) and lymphocytes (%), and in platelet parameter, i.
e. mean platelet volume (MPV), which were observed in
CDPCP-treated Oct1-/- mice but not in Oct1+/+ mice
(p<0.05, data not shown). The higher plasma platinum
concentration in Oct1-/- mice supported greater hemato-
logical toxicity of CDPCP in these mice (Fig. 6a; p<0.005).
Histological examination of intestine showed no signs of
intestinal toxicity in either Oct1+/+ or Oct1-/- mice
following CDPCP treatment, although significantly higher
intestinal accumulation of CDPCP in Oct1+/+ mice was
observed (Fig. 6d, p<0.05).
Toxicity Study of Oxaliplatin in Oct1 Wild-Type
and Oct1-/- Mice
To assess the role of Oct1 in the toxicities associated with
oxaliplatin treatment, especially the hepatotoxicity, the
Oct1+/+ and Oct1-/- mice (n=5 per group) were treated
with 6 mg/kg oxaliplatin or saline via i.p. injection once
daily for a total of 5 days. Oxaliplatin caused more severe
body weight loss in Oct1+/+ mice than in Oct1-/- mice; the
relative body weight loss in Oct1+/+mice was 15.1%,
whereas the relative body weight loss in Oct1-/- mice was
6.8%. Although there was a significantly greater hepatic
accumulation of oxaliplatin in Oct1+/+ mice, no difference
was observed in liver size or activities of three liver-
associated enzymes: ALT, AST and ALKP between
Oct1+/+ and Oct1-/- mice, respectively (data not shown).
The liver histopathology examination showed no clear sign
of liver damage associated with oxaliplatin treatment in
either Oct1+/+ or Oct1-/- mice. The data suggest that the
hepatic toxicity of oxaliplatin observed in humans was not
observed under the conditions used in this study, and a clear
role for Oct1 in oxaliplatin-induced hepatotoxicity could not
be established. The effect of Oct1 deletion on body weight was
striking and suggests that Oct1 plays a role in the overall
toxicity of oxaliplatin in the mice. Since oxaliplatin was not
hepatotoxic under the conditions used in this study, we could
not assess the effect of Oct1 on hepatotoxicity of oxaliplatin.
The dosing regimen or dosing route used in our study might
not be appropriate to elicit the hepatic toxicity.
Fig. 6 Platinum concentrations in plasma and various tissues collected from the toxicity study. Oct1-/- and Oct1+/+ mice were treated with saline or
CDPCP via tail vein injection once weekly for a total 3 weeks (at least 9 animals per group). The mice were fasted for at least 16 h before sacrifice. Blood
(A), liver (B), kidney (C), and intestine (D) were harvested 24 hrs after the last dose. Platinum was measured by ICP-MS. Data are presented as the
mean ± SD. * P<0.05; ** P<0.005.
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Oct1 Deletion Resulted in Enhanced Expression
of Oct2 and Oct3 in Various Tissues
mRNA levels of Oct2, Oct3, Ent1, Mate1 and Ctr1 in
various tissues were determined by quantitative RT-PCR.
The expression levels of Oct2 in liver was increased by
2.6-fold in Oct1-/- mice compared with Oct1+/+ mice
(Fig. 7a; p<0.05). The increase of Oct2 expression in
kidney and intestine of Oct1-/- mice was 1.8- and 2.5-fold
compared with Oct1+/+ mice, respectively. However,
these changes did not reach statistical significance due to
the relatively large variation (Fig. 7b, c; p>0.05). The
expression of Oct3 in liver in Oct1-/- mice was 5.7-fold of
that in Oct1+/+ mice (Fig. 7d, p<0.001). There was no
change in the expression levels of Ent1, Mate1 and Ctr1 in
liver between Oct1+/+ mice and Oct1-/- mice.
DISCUSSION
Though shown to be a potent anti-tumor platinum
compound, CDPCP was never tested clinically. Because
of its positive charge, the drug may have been thought to
have poor pharmacokinetic characteristics. In recent stud-
ies, OCT1 was shown to play a role in the cellular uptake
and consequent cytotoxicity of CDPCP in cell lines over-
expressing OCT1 (25). Accordingly, we hypothesized that
OCT1 mediates the uptake of CDPCP in vivo in various
tissues, particularly the intestine and liver, and that OCT1-
mediated transmembrane flux may result in a favorable
pharmacokinetic and toxicity profile for CDPCP. To test
our hypothesis, we performed a comprehensive pharmaco-
kinetic analysis using genetically modified Oct1-/- mice in
this study. The results suggest that deletion of Oct1 not only
decreased the uptake of cellular platinum but also reduced
the level of platinum-DNA adduct formation in hepatocytes
after CDPCP exposure (Fig. 2). These results are in
agreement with those in cells transfected with human OCT1
(25), although the fold difference in platinum levels between
hepatocytes harvested from Oct1+/+ versus Oct1-/-mice was
much less than that between HEK293 cells over-expressing
human OCT1 and control cells (25). These differences were
not due to species differences between mOct1 and hOCT1,
since our data suggest that CDPCP is a comparable or better
substrate of mOct1 than of hOCT1 (Fig. 1). Drug-
metabolizing enzymes and drug transporters normally are
lost by liver cells in culture as a consequence of the
adaptation of cells to the in vitro environment. Lecureu et al.
reported that hepatocytes maintained in primary culture for
several days were known to not only lose expression of
albumin and cytochrome P-450 but also displayed low levels
of OCT1 expression and activity (31). Studies from our
laboratory also confirmed that the expression level of Oct1 in
primary hepatocytes cultured from mouse liver was consid-
Fig. 7 Effects of Oct1 deletion on the expression of Oct2 and Oct3 in various tissues in mice. The expression of Oct2 in liver (A), kidney (B) and intestine
(C) and the expression of various drug transporters in liver (D) were determined by quantitative RT-PCR. Various tissues were harvested from age-
matched Oct1+/+ and Oct1-/- mice. Total RNA was extracted from these tissues and reverse-transcribed. The synthesized cDNA was subject to qRT-
PCR using an Oct2, Ent1, Oct3, Mate1 and Ctr1 probes. The amplification of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA was used as
an internal control. Data are presented as the mean ± SD (n=3). * P<0.05; ** P<0.001.
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erably lower than that in mouse liver (data not shown),
suggesting that the isolation and culture procedures likely
resulted in a reduced expression level of the Oct1 protein
and therefore a reduction in the observed effect of Oct1 in
the isolated hepatocytes.
The significantly higher hepatic and intestinal accumu-
lation of CDPCP in Oct1+/+ mice was consistent with the
abundance of Oct1 in liver and intestine of rodents (12,13).
Normalization of tissue platinum levels to plasma concen-
trations of CDPCP excluded the effects of different plasma
exposure on the uptake of CDPCP into the various tissues.
Although there is strong Oct1 expression in the kidney of
mice (12,13,32), it was notable that no differences were
observed in the normalized levels of platinum in the kidneys
of Oct1+/+ versus Oct1-/- mice. This may be explained by
the redundant function of Oct1/2 in the rodent kidney, and
the Oct2 strongly expressed in the kidney can completely
compensate for the loss of Oct1. Previously, CDPCP was
shown to be a substrate of OCT2 (25). It is notable that
enhanced expression of Oct2 and Oct3 in the liver of
Oct1-/- mice may have resulted in a reduction in the
observed effect of Oct1 on CDPCP uptake in the liver
(Fig. 7a and d).
Consistent with the high hepatic accumulation in
Oct1+/+ mice, the hepatotoxicity of CDPCP was more
prominent in these mice, as demonstrated by the increased
liver-to-body-weight ratio, decreased total serum protein
levels, increased serum glucose levels and histological
changes at 90 mg/kg in the Oct1 wild-type mice. The low
BUN in the wild-type mice treated with CDPCP is also
consistent with hepatotoxicity in these mice. A low BUN
usually has little significance, but its causes include liver
problems, malnutrition (insufficient dietary protein), or
excessive alcohol consumption. Although there was greater
hepatic toxicity in Oct1+/+ mice, the level of toxicity was
considered mild and reversible. If CDPCP is developed as an
anti-cancer drug, hepatic toxicity may not be a concern.
Recently, use of oxaliplatin has been associated with
development of hepatic lesions, which include sinusoidal
alteration, portal hypertension, increase in transami-
nases, gamma glutamyltranspeptidase and alkaline phos-
phatase, and steatohepatitis (6,33). In our study, the role
of Oct1 in the tissue accumulation and the pharmacoki-
netics of oxaliplatin was proven to be minimal, and
oxaliplatin was not hepatotoxic under the conditions used
in this study. However, total plasma platinum levels may
not reflect platinum complexes available for DNA and
protein binding, anti-tumor effects and toxicity of the
oxaliplatin. The fact that oxaliplatin administration
resulted in a greater reduction in body weight in the
wild-type mice in comparison to the Oct1 knockout mice
may suggest that Oct1 plays a role in the systemic
toxicities of oxaliplatin.
In this study, we made an unexpected observation that
Oct1 deletion markedly increased the renal toxicity of
CDPCP in Oct1-/- mice, which was revealed by much
greater Kim-1 mRNA expression level and histological
changes of tubular cast formation and degeneration of
tubular cells in Oct1-/- mice (Fig. 5b, c.II, and c.III). The
differential localization of organic cation transporters Oct1
and Oct2 in the basolateral membrane of rodent kidney
proximal tubules may account for the greater kidney
toxicity in Oct1-/- mice. In particular, Oct1 was shown to
be concentrated in the early proximal tubules in the renal
cortex, whereas Oct2 was abundant in the late proximal
tubules in the outer stripe of the outer medulla (34,35). In
the report by Jonker et al. of the relative impact of Oct1 and
Oct2 on the clearance of TEA (36), they observed that
elimination of neither Oct1 nor Oct2 resulted in a decrease
in renal TEA clearance, whereas elimination of both
transporters eliminated TEA secretion. These data suggest
that there is sufficient Oct1 transport capacity in the early
renal proximal tubules to effectively clear the blood of
substrate before it reaches the downstream Oct2-expressing
cells of the late renal proximal tubules. CDPCP is an
excellent substrate of both OCT1 and OCT2 (25). In
Oct1-/- mice, CDPCP will be secreted by Oct2-expressing
cells in late renal proximal tubules. The greater exposure of
the late proximal tubule to CDPCP may contribute to the
enhanced toxicity of CDPCP observed in the Oct1-/- mice.
Further, Oct2 is likely to localize in the outer strip of the
outer medulla and may produce a localized accumulation
of CDPCP in this region. The outer medulla was the region
most damaged by CDPCP (Fig. 5c.II and III).
The pharmacokinetics of CDPCP were consistent with
the pharmacokinetics observed previously for oxaliplatin
and picoplatin, suggesting that the drug has a pharmaco-
kinetic profile similar to clinically used anti-cancer platinum
agents. Deletion of Oct1 resulted in a reduction in the
clearance and volume of distribution of CDPCP, which
may be explained by the differences in the distribution of
CDPCP to the tissues with high Oct1 expression, in
particular, liver and intestine. The higher plasma platinum
concentrations and AUC in Oct1-/- mice in comparison to
Oct1+/+ mice can be attributed to the lower clearance and
volume of distribution in Oct1-/- mice. Since the renal
clearance of CDPCP was similar between Oct1+/+ and
Oct1-/- mice, the lower total clearance of CDPCP in the
Oct1-/- mice is likely due to a reduction in the uptake and
subsequent covalent binding of CDPCP in the liver and
intestine, organs that accumulate high levels of platinum.
Though other transporters may affect the disposition of
CDPCP, this study clearly demonstrates that Oct1 plays a
significant role in the pharmacokinetics of this drug. The
lack of an important role of Oct1 in the pharmacokinetics
of oxaliplatin may suggest a lower specificity of oxaliplatin
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for Oct1 and that other transporters (or diffusion) may
contribute to its tissue distribution and pharmacokinetics.
In this study, CDPCP exhibited excellent pharmacokinetic
properties, comparable to other clinically used platinum
analogs. Moreover, CDPCP appears to possess a favorable
toxicity profile, and Oct1 plays an important role in
determining the toxicity profile of CDPCP. Our study
supported the concept that by targeting drug influx
transporters, off-target toxicities, such as renal, hemato-
logical toxicities, can be spared. Whether CDPCP can be
used for targeted therapy of various cancers is worthy of
further investigation. Further, this study provides another
example of a drug distinct from metformin for which
OCT1 may play a profound role in its pharmacokinetics
and toxicities (4,6,7).
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